

A concept that meets surgeons' demands

One product – two components. One application - two outcomes. The unique combination of ancillary anaesthetic and viscoelastic serves two purposes: safety and comfort for both surgeon and patient.

"Some patients come to our center specifically because we use ZEISS VISTHESIA. Using VISTHESIA in our institution has been very beneficial for me in terms of workflow and patient satisfaction."

Prof. Ekkehard Fabian, MD, Rosenheim, Germany, AugenCentrum

"I believe ZEISS VISTHESIA is the standard of care for cataract surgery." Dr. Karin Wallentén, MD, PHD Växjö, Sweden, Växjö Hospital

"ZEISS VISTHESIA provides the **security** of knowing the patient has maximal comfort." Dr. Carlos Ruiz Lapuente, MD, Barcelona, Spain, Virgen del Rocío Hospital

"ZEISS VISTHESIA means more comfort for the patient and more comfort for the surgeon." Prof. Joseph Colin, MD, Bordeaux, France, Bordeaux University Medical School

VISTHESIA 1.0% VISTHESIA 1.5% VISTHESIA 1.0% intra VISTHESIA 1.5% intra



Hyaltech Ltd.

Starlaw Business Park Livingston EH54 8SF United Kingdom www.zeiss.com/ovd www.zeiss.com/med/contacts



Carl Zeiss Meditec AG

Goeschwitzer Strasse 51-52 07745 Jena Germany www.zeiss.com/ovd www.zeiss.com/med/contacts The contents of the brochure may differ from the current status of approval of the product or service offering in your country. Please contact our regional representatives for more information. Subject to changes in design and scope of delivery and due to ongoing technical development. VISTHESIA 1.0%, VISTHESIA 1.5%, VISTHESIA 1.0% intra and VISTHESIA 1.5% intra are registered trademarks of Carl Zeiss Meditec AG in Germany and/or other countries.





Three-step-guide and users' experience

ZEISS VISTHESIA ZEISS VISTHESIA intra

zeiss.com/ovd



VISTHESIA^{1,2}/VISTHESIA intra¹

More comfort through pain relief even in prolonged surgery

The first and only OVD which offers ancillary anesthesia and a viscous cohesive ophthalmic viscoelastic combined in one solution – providing enhanced comfort for peace of mind even during prolonged cataract surgery.

Intracameral viscous-cohesive OVD

- Containing sodium hyaluronate in a concentration of 1% and 1.5%, both with lidocaine (1%)
- VISTHESIA reflects a unique combination of sodium hyaluronate and ancillary lidocaine

Topical ampules

■ Preoperative topical application containing sodium hyaluronate (0.3%) with lidocaine (2%) that coats and hydrates the epithelial cells supporting clear vision into the eye.

ZEISS VISTHESIA

Three-step-guide

Are you a first-time VISTHESIA® user and have you used a particular dispersive or cohesive OVD before? Then, please take into consideration that each OVD has its own characteristic behavior.

Step 1

Preoperatively in the non-sterile environment

Apply the content of one VISTHESIA Topical ampule to the surface of the eye prior to moving the patient into the OR for surgery. The effect of lidocaine is quick and will be enhanced through VISTHESIA Intracameral later during the procedure. The patient should blink a few times to ensure the solution is spread over the cornea. Proceed with preparing the patient for surgery.

Step 2

Prior to commencing surgery in the sterile environment

When the patient has been prepared for surgery, apply a few more drops of VISTHESIA Topical shortly (30-60 seconds) before the first incision to support pain relief and to maintain corneal hydration.

Step 3

Intraoperative

As you would routinely use your cohesive OVD, inject VISTHESIA Intracameral into the anterior chamber after creation of the main incisions, or as required throughout the surgical procedure.

Important to note:

- Complete removal of the viscoelastic is very important by irrigation/aspiration.
- Post-operative patient monitoring should be performed as usual.



...the overall comforter

References

- F. Poyales-Galan, G. Pirazzoli, "Clinical Evaluation of Endothelial Cell Decrease with VISTHESIA in Phacoemulsification Surgery, Journal of Cataract & Refractive Surgery, Nov. 2005, Vol. 31
- L. Werner et al., "Part I: Toxicity to corneal endothelial cells in a rabbit model", Journal of Cataract & Refractive Surgery, March 2003, Vol. 29
- L. Werner et al., "Part II: Toxicity to intraocular structures after phacoemulsification in a rabbit model", Journal of Cataract & Refractive Surgery, March 2003, Vol. 29
- L. Werner et al., "Part III: Removal Time of OVD/viscoanesthetic solutions from the capsular bag of postmortem eyes", Journal of Cataract & Refractive Surgery, March 2003, Vol. 29
- P. Bournas, "The use of a new viscoelastic substance combined with anesthetic in cataract surgery by phacoemulsification", Ann. Ital. Chir. 2005, 76 pp 383-389.
 G. Auffarth, Prospective Safety Study on the Viscoelastic VISTHESIA: 22nd Congress of

the DGII 2008, KV12, Klin Monatsbl Augenheilkd 2008; 225: Suppl 1, pp 1 - pp 24.

 $^{^{\}mbox{\tiny 1}}$ VISTHESIA 1.0% and VISTHESIA 1.5% are not for sale in the UK or Portugal

² Please find more information about ZEISS VISTHESIA on the product datasheet available on the website: www.zeiss.com/ovd